You can download the current version of DIRA 1.0, which has been released on March 01, 2018. The drug-induced rhabdomyolysis classification (DIR) scheme was developed based on drug labeling information. Furthermore, post-marketing DIR surveillance data from U.S. Food and Drug Administration (FDA) Spontaneous Adverse Events Reporting System (FAERS) were extracted to represent incidence information of DIR. In addition, drug properties such as chemical structure, therapeutic categories, and daily dose were also included.
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.